Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report for the Scottish Medicines Consortium (SMC)
First-line treatment of adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant: SMC2804

About this release

This release by Public Health Scotland (PHS) uses information from the National SACT dataset.

This work was requested by the Scottish Medicines Consortium (SMC) to support their decision-making processes. Isatuximab in combination with bortezomib, lenalidomide and dexamethasone as a first-line treatment for adult patients with newly diagnosed multiple myeloma, who are ineligible for an autologous stem cell transplant (ASCT) (SMC2804) is being assessed for use by NHSScotland.

The aim of this work was to capture real-world evidence (RWE) from Scotland on the use of first-line systemic anti-cancer therapy (SACT) for adult patients with newly diagnosed multiple myeloma who are ineligible for an ASCT. Details of the presumptions made to identify this cohort are described in Section 2.3.1. This work will enable SMC members to assess the relevance of information, provided as part of the assessment process for SMC2804, to patients in Scotland.

The objectives were to:

• Determine the number of patients who received first-line SACT for the treatment of newly diagnosed multiple myeloma who were ineligible for an ASCT.
• Describe the baseline characteristics of patients who received first-line SACT for the treatment of newly diagnosed multiple myeloma who were ineligible for an ASCT.
• Provide information on SACT usage for the first-line treatment of newly diagnosed multiple myeloma in patients who are ineligible for ASCT.